 |
| Anno I | Numero 7 | Novembre 2016 |
| Comitato scientifico editoriale: Paolo A. Ascierto, Vanna Chiarion-Sileni Editore: Intermedia – Direttore Responsabile: Mauro Boldrini |
| Notizie dalla ricerca |
| Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial |
| Results from phase 2 and 3 trials in patients with advanced melanoma have shown significant improvements in the proportion of patients achieving an objective response and prolonged progression-free survival with the combination of nivolumab (an anti-PD-1 antibody) plus ipilimumab (an anti-CTLA-4 antibody) compared with ipilimumab alone. We report 2-year overall survival data from a randomised controlled trial assessing this treatment in previously untreated advanced … |
| Continua a leggere |
| Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination |
| Inhibition of immune checkpoints using anti-programmed cell death-1 (PD-1) or anti cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibodies has revolutionized the management of patients with advanced-stage melanoma and is among the most promising treatment approaches for many other cancers. Use of CTLA-4 and PD-1 inhibitors, either as single agents, or in combination, has been approved by the US FDA for the treatment of metastatic … |
| Continua a leggere |
| Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma |
| With the wide use of anti-PD-1 therapy, an increasing number of patients progress under treatment. Combined immunotherapy with anti-CTLA-4 and anti-PD-1 antibodies induces higher response rates as first-line treatment in comparison to single-agent therapy, however, with substantial toxicity since the combination of ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) induced 55% grade 3/4 treatment-related adverse events and treatment discontinuation rates of 39%. In this case … |
| Continua a leggere |
| Toxicity management of immunotherapy for patients with metastatic melanoma |
| Checkpoint inhibitors have revolutionized the treatment of patients with metastatic melanoma offering improved responses and significant survival benefit. These agents are now approved for the treatment of metastatic melanoma, squamous and non-squamous non-small cell lung cancer (NSCLC) and kidney cancer, while they are now being investigated in a range of other malignancies. In addition, another anti-PD-L1 monoclonal antibody (atezolizumab) was recently approved for … |
| Continua a leggere |
| Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma |
| Immune checkpoint inhibition with ipilimumab has revolutionized cancer immunotherapy and significantly improved outcomes of patients with advanced malignant melanoma. Local peripheral treatments (LPT), such as radiotherapy or electrochemotherapy, have been shown to modulate systemic immune responses, and preliminary data have raised the hypothesis that the combination of LPT with systemic immune checkpoint blockade might be beneficial. Clinical data from 127 consecutively … |
| Continua a leggere |
| Are there, or shall we discover, biomarkers to guide PD-1 inhibition? |
| Despite the recent success of PD-1/PD-L1-directed immunotherapy in a number of different malignancies, there are currently no effective biomarkers available to predict patient response to treatment. This question is particularly important because these immunotherapy agents are expensive and have significant toxicity profiles. Early data are emerging on biomarkers such as PD-L1 expression; however, it is clear that further studies are needed to identify alternative biomarkers and to improve … |
| Continua a leggere |
| Appuntamenti AIOM |
| 4th International Conference 'Translational Research in Oncology' |
| Meldola (FC), 8 novembre 2016 Forlì, 9 – 11 novembre 2016 Informazioni disponibili sul sito dell'evento: www.fictro2016.it |
| Immuno-Oncologia: Stato dell'Arte e Update |
| Cagliari, 9 novembre 2016 Settima tappa del Progetto itinerante AIOM di Immuno-Oncologia. Evento riservato ai Soci AIOM Sardegna Le eventuali spese di trasporto saranno rimborsate con apposito modulo consegnato direttamente in sede congressuale |
| Nuove frontiere diagnostico-terapeutiche nelle neoplasie polmonari, renali e nel melanoma |
| Varese, 12 novembre 2016 |
| XXII Congresso Nazionale IMI – Intergruppo Melanoma Italiano Multidisciplinarità e Integrazione Intorno al Paziente |
| Ragusa, 13 – 15 novembre 2016 |
| Master Course IMI Management del paziente con melanoma. Dalla ricerca alla terapia |
| Milano, 25 – 26 novembre 2016 |
| First International Congress Clinical Needs and Translational Research in Oncology |
| Reggio Emilia, 28 – 29 novembre 2016 |
| Melanoma Bridge 2016 |
| Napoli, 30 novembre – 3 dicembre 2016 |
| Immunotherapy Bridge 2016 |
| Napoli, 30 novembre 2016 |
Questi e altri appuntamenti si possono consultare sul sito AIOM www.aiom.it |
| Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001 Per contattare la redazione e commentare le notizie clicca qui: redazione Per consultare i numeri arretrati della newsletter clicca qui: archivio Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI |
Questo progetto è stato realizzato con il contributo di  |